The Oncotype DX® Genomic Prostate Score™ assay
The Oncotype DX® Genomic Prostate Score™ (GPS) assay is the only genomic assay designed for men with clinically low-risk or favorable intermediate-risk cancer to help make treatment decisions at the time of diagnosis. The assay analyzes prostate cancer gene activity to predict disease aggressiveness.
The Oncotype DX GPS assay provides more specific and individualized information about prostate cancer aggressiveness by:
• Providing a GPS result ranging from 0-100 that corresponds to the biologic aggressiveness of the tumor.
• Measuring biology through the expression of 17 genes across four important genetic pathways and, in conjunction with clinical risk factors, predicts the likelihood of adverse pathology, prostate cancer death, and metastasis at 10 years. 1
The Oncotype DX GPS assay has been developed and studied in over 5,000 patients.1-14 The results from the assay refine risk assessment, help guide treatment decisions, and potentially impact patient quality of life. For example, the results might give a low- or favorable intermediate-risk patient the additional confidence he needs to pursue active surveillance, delaying or even completely avoiding the side effects of more aggressive treatment options like prostatectomy or radiation therapy.
For further information, please go to oncotypeiq.com/en
REFERENCES
1. Klein et al. Eur Urol. 2014.
2. Cullen et al. Eur Urol. 2015.
3. Van Den Eeden et al. Eur Urol. 2017.
4. Eure et al. AUA 2017.
5. Brand et al. Urology. 2016.
6. Knezevic et al. BMC Genomics. 2013.
7. Badani et al. Urol Pract. 2015.
8. Dall’Era et al. Urol Pract. 2015.
9. Lynch et al. Am J Manage Care 2018.
10. Albala et al. Rev Urol. 2016.
11. Bonham et al. USCAP 2016.
12. Salmasi et al. J Urol. 2018.
13. Eure et al. Urology 2017.
14. Leapman et al. PloS One. 2017.
The Oncotype DX GPS assay provides more specific and individualized information about prostate cancer aggressiveness by:
• Providing a GPS result ranging from 0-100 that corresponds to the biologic aggressiveness of the tumor.
• Measuring biology through the expression of 17 genes across four important genetic pathways and, in conjunction with clinical risk factors, predicts the likelihood of adverse pathology, prostate cancer death, and metastasis at 10 years. 1
The Oncotype DX GPS assay has been developed and studied in over 5,000 patients.1-14 The results from the assay refine risk assessment, help guide treatment decisions, and potentially impact patient quality of life. For example, the results might give a low- or favorable intermediate-risk patient the additional confidence he needs to pursue active surveillance, delaying or even completely avoiding the side effects of more aggressive treatment options like prostatectomy or radiation therapy.
For further information, please go to oncotypeiq.com/en
REFERENCES
1. Klein et al. Eur Urol. 2014.
2. Cullen et al. Eur Urol. 2015.
3. Van Den Eeden et al. Eur Urol. 2017.
4. Eure et al. AUA 2017.
5. Brand et al. Urology. 2016.
6. Knezevic et al. BMC Genomics. 2013.
7. Badani et al. Urol Pract. 2015.
8. Dall’Era et al. Urol Pract. 2015.
9. Lynch et al. Am J Manage Care 2018.
10. Albala et al. Rev Urol. 2016.
11. Bonham et al. USCAP 2016.
12. Salmasi et al. J Urol. 2018.
13. Eure et al. Urology 2017.
14. Leapman et al. PloS One. 2017.
Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Genomic Prostate Score, GPS, Recurrence Score, Colon Recurrence Score, and Genomic Prostate Score are trademarks or registered trademarks of Genomic Health, Inc. Used under license.